Phase I Pharmacokinetic (PK) & Safety Study of TRPH- 222 in Patients with Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma

Time: 3:00 pm
day: day 1 track 3 pm


• Summarize the SMARTag
technology and Phase 1 study
• Review of the safety and efficacy
of TRPH-222 in R/R NHL
• Presenting our thoughts on
moving ADCs beyond the
delivery of cytotoxic payloads